Imatinib mesylate for platelet-derived growth factor receptor-beta–positive Erdheim-Chester histiocytosis
Open Access
- 1 June 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (11), 5413-5415
- https://doi.org/10.1182/blood-2008-03-148304
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Imatinib as a Treatment Option for Systemic Non-Langerhans Cell HistiocytosesArchives of Dermatology, 2007
- Variability in the efficacy of interferon‐α in Erdheim‐Chester disease by patient and site of involvement: Results in eight patientsArthritis & Rheumatism, 2006
- Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-αBlood, 2005
- Cardiovascular Involvement, an Overlooked Feature of Erdheim-Chester DiseaseMedicine, 2004
- Imatinib targets other than bcr/abl and their clinical relevance in myeloid disordersBlood, 2004
- Imatinib Mesylate for Cerebral Langerhans'-Cell HistiocytosisThe New England Journal of Medicine, 2004
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaThe New England Journal of Medicine, 2002
- Erdheim-Chester Disease Clinical and Radiologic Characteristics of 59 CasesMedicine, 1996
- Über LipoidgranulomatoseVirchows Archiv, 1930